AT 101

Drug Profile

AT 101

Alternative Names: (-)-gossypol; AT-101; Bcl-2/xL inhibitor - 3SBio; R-(-)-gossypol acetic acid

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer 3SBio; Ascenta Therapeutics; Mayo Clinic; National Cancer Institute (USA)
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Multiple myeloma
  • Preclinical Leukaemia; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Glioblastoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 20 Oct 2016 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02697344)
  • 11 Mar 2016 Mayo Clinic plans a phase I/II trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (NCT02697344)
  • 29 Jan 2016 Preclinical trials in Leukaemia in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top